作者: Christopher G. Kanakry , Ephraim J. Fuchs
DOI: 10.1007/978-3-319-06444-4_17
关键词:
摘要: Patients lacking a human leukocyte antigen (HLA)-matched donor have alternative stem cell sources, including HLA-haploidentical relatives, partially HLA-mismatched unrelated adult donors, or umbilical cord blood (UCB). Historically, the main challenge for UCB transplantation (UCBT) has been delayed posttransplant immune reconstitution, whereas allogeneic hematopoietic (allo-HSCT; haplo-HSCT) bidirectional alloreactivity resulting in high incidences of graft failure and graft-versus-host disease (GVHD). Recent phase II trials established clinical equipoise currently active, randomized III trial either double UCBT haplo-HSCT. In this chapter, we will review results studies haplo-HSCT lessons hope to learn from first comparison.